Navitoclax dihydrochloride is a small molecule commercialized by AbbVie, with a leading Phase III program in Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF). According to Globaldata, it is involved in 37 clinical trials, of which 23 were completed, 10 are ongoing, and 4 were terminated. GlobalData uses proprietary data and analytics to provide a complete picture of Navitoclax dihydrochlorides valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
The revenue for Navitoclax dihydrochloride is expected to reach an annual total of $315 mn by 2034 in the US based off GlobalDatas Expiry Model. The drugs revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drugs phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
Navitoclax dihydrochloride Overview
Navitoclax (ABT-263, RG7433) is under development for the treatment of primary myelofibrosis, metastatic melanoma, solid tumor, relapsed/refractory acute myeloid leukemia, non-small cell lung cancer, post polycythemia vera, myelofibrosis, hepatocellular carcinoma, acute lymphocytic leukemia, lymphoblastic lymphoma, myelodysplastic syndrome and post-essential thrombocythemia myelofibrosis. It is administered through oral route. The drug candidate blocks the function of pro-survival Bcl-2 family proteins.
It was also under development for the treatment of small-cell lung cancer, metastatic hormone-refractory prostate cancer, hematologic malignancies including front-line chronic lymphocytic leukemia, relapsed or refractory chronic lymphocytic leukemia, myelofibrosis, primary myelofibrosis, post-polycythemia vera myelofibrosis, post-essential thrombocythemia myelofibrosis, polycythemia vera and essential thrombocythemia, B-cell chronic lymphocytic leukemia (CLL), relapsed diffuse large B-cell lymphoma, relapsed or refractory lymphoid malignancies, multiple myeloma and acute lymphoblastic leukemia.
AbbVie Overview
AbbVie is a specialty biopharmaceutical company, which discovers, develops, manufactures, and commercializes drugs for the treatment of chronic and complex diseases. Its drugs are indicated for the treatment of metabolic and rheumatological diseases, neurological disorders, skin diseases, rheumatoid arthritis, pain related to endometriosis, pediatric Crohn’s disease, cancer, and other serious health conditions. AbbVie is also advancing its pipeline programs for the treatment of Crohn’s disease, Parkinson’s disease, neurological disorders, aesthetics, and other autoimmune diseases. The company markets its products directly to wholesalers, distributors, healthcare facilities, government agencies, specialty pharmacies, and independent retailers. The company has operations in the Americas, Asia-Pacific, Europe, the Middle East and Africa. AbbVie is headquartered in North Chicago, Illinois, the US.
The company reported revenues of (US Dollars) US$54,318 million for the fiscal year ended December 2023 (FY2023), a decrease of 6.4% over FY2022. In FY2023, the companys operating margin was 23.5%, compared to an operating margin of 31.2% in FY2022. In FY2023, the company recorded a net margin of 9%, compared to a net margin of 20.4% in FY2022.
The company reported revenues of US$12,310 million for the first quarter ended March 2024, a decrease of 13.9% over the previous quarter.
For a complete picture of Navitoclax dihydrochlorides valuation, buy the drugs risk-adjusted NPV model (rNPV) here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.